New Key Statistics Module, Z-Score and F-Score
NAS:ALLO Key Ratios
| Market Cap $ M | 544.73 |
| Enterprise Value $ M | 228.92 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 1.06 |
| Price/Sales | 2,600.36 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -1.64 |
| Beneish M-Score | -3.67 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 17.40 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.83 |
| EV-to-EBITDA | -0.87 |
| PEG | -- |
| Shares Outstanding M | 209.11 |
| Net Margin (%) | -1,342,523.81 |
| Operating Margin % | -1,289,761.91 |
| Pre-tax Margin (%) | -1,342,523.81 |
| Quick Ratio | 12.25 |
| Current Ratio | 12.25 |
| ROA % (ttm) | -41.96 |
| ROE % (ttm) | -52.31 |
| ROIC % (ttm) | -123.98 |
| Dividend Yield % | -- |
| Altman Z-Score | -1.56 |
ALLO Number of Guru Trades
ALLO Volume of Guru Trades
Gurus Latest Trades with NAS:ALLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:ALLO is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Allogene Therapeutics Inc Insider Transactions
No Available Data
News about NAS:ALLO
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers